Home › Funds › Ikarian Capital, LLC › IVA
Ikarian Capital, LLC position in IVA
INVENTIVA SA · Health Care
Ikarian Capital, LLC reported holding 1,129,101 shares of IVA (INVENTIVA SA) in its Q2 2026 13F filing — a position valued at US$4.2M, representing 0.67% of its reported portfolio and ranking #48 among its reported holdings. Ikarian Capital, LLC has disclosed IVA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's IVA position evolved
Ikarian Capital, LLC first disclosed a stake in IVA in Q4 2025 at 502,601 shares (US$2.3M). The position peaked in Q1 2026 at 1,429,101 shares, worth US$7.8M. Across 3 filings, Ikarian Capital, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,129,101 shares valued at US$4.2M — a reduction of -300,000 shares quarter over quarter.. Notable position changes include a 184% increase in Q1 2026 (shares fell 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 502.60K | $2.33M | New |
| Q1 2026 | 1.43M | $7.84M | Add |
| Q2 2026 | 1.13M | $4.15M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IVA and 13F data
IVA (INVENTIVA SA) is a Health Care company. 94 other funds we track also report a position in IVA — the largest reported positions include Caligan Partners LP (US$30.9M), Samsara BioCapital, LLC (US$23.9M), Paradigm Biocapital Advisors LP (US$15.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IVA
- Caligan Partners LP 8.16M sh · $30.86M · Q2 2026
- Samsara BioCapital, LLC 6.31M sh · $23.87M · Q2 2026
- Paradigm Biocapital Advisors LP 4.00M sh · $15.12M · Q2 2026
- ADAR1 Capital Management, LLC 3.61M sh · $13.63M · Q2 2026
- Andera Partners 3.63M sh · $13.41M · Q3 2026
- SymBiosis Capital Partners, LLC 2.35M sh · $13.06M · Q1 2026
- Trails Edge Capital Partners, LP 2.66M sh · $10.05M · Q2 2026
- Squadron Capital Management LLC 2.44M sh · $9.20M · Q2 2026
- Patient Square Capital LP 1.97M sh · $7.44M · Q2 2026
- NEXTBio Capital Management LP 1.79M sh · $6.76M · Q2 2026
- Yu Fan 1.50M sh · $5.67M · Q2 2026
- NEA Management Company, LLC 1.46M sh · $5.53M · Q2 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held IVA?
Ikarian Capital, LLC has disclosed IVA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Ikarian Capital, LLC's current position in IVA?
As of Q2 2026, Ikarian Capital, LLC holds 1.13M shares of IVA (INVENTIVA SA), valued at $4.15M, representing 0.67% of its reported portfolio and ranking #48.
Has Ikarian Capital, LLC been buying or selling IVA?
In the latest 13F filing (Q2 2026), Ikarian Capital, LLC reduced its position in IVA. The position peaked in Q1 2026 at 1.43M shares.
Which other funds hold IVA?
Other major institutional holders of IVA include Caligan Partners LP, Samsara BioCapital, LLC, Paradigm Biocapital Advisors LP, among 94 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.